Optimal therapy of HIV/HCV co-infected patients with direct acting antivirals
|
|
- Toby Nelson
- 5 years ago
- Views:
Transcription
1 Liver International ISSN REVIEW ARTICLE Optimal therapy of HIV/HCV co-infected with direct acting antivirals J urgen K. Rockstroh 1,2 1 Department of Internal Medicine I, Bonn University Hospital, Bonn, Germany 2 German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Bonn, Germany Keywords HIV hepatis C liver disease direct acting antivirals cirrhosis Abbreviations ART, antiretroviral therapy; cart, combined antiretroviral therapy; DAA, direct acting antivirals; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IFN, interferon; IQR, interquartile range; PI, protease inhibitors; RBV, ribavirin; SVR, sustained viral response. Correspondence Prof. Dr J urgen Kurt Rockstroh, Department of Medicine I, Bonn University Hospital, Sigmund-Freud-Str. 25, Bonn 53105, Germany Tel: Fax: juergen.rockstroh@ukb.uni-bonn.de Abstract The development of direct acting antivirals (DAAs) against the hepatitis C virus (HCV) has revolutionized treatment paradigms for HCV in HIV coinfected subjects. In the era of DAAs, HIV/HCV co-infected have the same cure rates of over 90% with interferon (IFN)-free DAA combinations. Therefore, guidelines no longer separate mono- and co-infected subjects. Indications for HCV therapy and DAA drug selection have become the same for all. The only special consideration in HIV/HCV co-infected subjects is the need to check for drug drug interactions between HIV and HCV drugs, especially HIV and HCV protease inhibitors which have a high risk of clinically significant drug interactions. Because of the faster progression of fibrosis and the higher risk of hepatic decompensation in co-infected subjects, even with combination antiretroviral (ART) therapy, the availability of modern HCV treatments needs to be extended and HCV therapy should be discussed in all co-infected. DOI: /liv Key points 2.8 Million (IQR Million) HIV infected subjects have HCV-antibodies worldwide. HCV associated liver disease has emerged as a main cause of morbidity and mortality in HIV/HCV co-infection in the era of combined antiretroviral therapy (cart). In the era of DAA there is no longer any separation between mono- and confected for the indications of HCV treatment or drug choice. DAA-based IFN-free combination therapy is the optimal HCV therapy with expected HCV cure rates >90% for genotypes 1 and 3 6. Sofosbuvir and ribavirin are the new gold standard therapy in genotype 2. Before beginning HCV therapy, concomitant HIV therapy needs to be checked for potential drug drug interactions. Background As a result of shared modes of transmission, the prevalence of hepatitis C virus (HCV) is high in with human immunodeficiency virus (HIV) co-infection. Indeed, worldwide, an estimated 2.8 million [IQR (interquartile range) Mill] HIV-infected subjects also have antibodies against HCV, with most infections in Africa and Southeast Asia, emphasizing the need for HCV treatment and management strategies in these areas of the world (1). In Europe, one of four HIV also has chronic HCV, with much higher rates of co-infection in Eastern and Southern Europe than in Central and Northern Europe (2). Because the natural history of HCV is accelerated in with HIV, and especially in those with advanced immune deficiency and because of the availability of combination antiretroviral therapy, HCV associated liver disease has become a main cause of morbidity and mortality in HIV/HCV infected individuals (3). Unfortunately, pegylated interferon (IFN) and ribavirin (RBV) combination therapy is associated with significantly lower HCV cure rates in HIV/HCV coinfected than in HCV mono-infected subjects (4). This lower efficacy and the severity of IFN/RBV associated adverse events have limited the use of HCV therapies in this special patient population (5). However, in early pilot trials with direct acting antivirals (DAAs), in particular first generation HCV protease inhibitors telaprevir and boceprevir, similar increased cure rates were 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 51
2 Optimal therapy of HIV/HCV co-infected with DAAs Rockstroh reported in both na ıve and treatment-experienced HIV/ HCV co-infected as well as in with HCV infection alone, with cure rates between 63 and 80% (6 8). With the marketing of IFN-free DAA combinations and potential of cure rates above 95%, as well as shorter treatment without IFN and even without RBV, in the near future telaprevir/boceprevir and IFN may no longer be a component of the HCV treatment and management strategy. Because of the similar sustained viral response (SVR) rates in HCV mono- and HIV/HCV co-infected subjects, major guidelines such as the recent EASL updated HCV clinical practice guidelines, no longer differentiate between HIV/HCV co-infected and HCV mono-infected (9). Indeed indications and treatment choices are now the same. The only remaining issue is the need to check for drug drug interactions between antiretroviral HIV drugs and DAAs. The following review provides practical guidelines on the use of DAAs in HIV/HCV co-infection and discusses who should be treated and when and how to treat. However, it should be kept in mind that progress is being made in HCV therapy at an incredibly fast pace so that treatment strategies are subject to constant change with the development of even more potent new DAA drug combinations. It should also be emphasized that access to these medical advances varies in the different European countries probably because of the high cost of the new DAAs, which is unfortunately a major barrier to these life-saving medications. Practical considerations for HCV therapy in HIV/ HCV co-infection Indication for therapy and patient selection: treat with significant fibrosis HCV treatment can potentially eradicate HCV within a defined period. This is also beneficial to the management of HIV co-infected, thus all co-infected individuals should be considered for treatment when the benefits of therapy outweigh the risks. This must also be considered within the context of the faster progression of liver fibrosis in HIV/HCV co-infection and the improved outcome in treated with direct acting antivirals (DAAs). Indeed, even with successful HIV therapy and persistent suppression of HIV replication, the risk of hepatic decompensation is still higher in HIV/HCV co-infected than in HCV mono-infected (10). Moreover achieving an SVR has also been associated with improved overall survival even in the lower stages of fibrosis (F0 F2) suggesting that HCV therapy provides benefits beyond the cure of HCV and may prevent the progression of liver disease (11). Nevertheless, fibrosis is not likely to progress with stable combined antiretroviral therapy (cart), making a wait and see approach a feasible strategy in HIV/HCV coinfected subjects with little or no fibrosis (F0 F1), especially since HCV drugs with even shorter treatment durations are expected on the market in the near future. For more advanced fibrosis, however, treatment should be considered because fibrosis has already developed and cirrhosis can occur. Because of limited resources, should be prioritized according to need (F3 and F4), an approach which is being adopted in most European countries at present. Figure 1 provides a management algorithm for newly diagnosed HCV. Which should be treated first: HIV or HCV? If chronic HCV is detected early in the course of HIV infection [before ART (antiretroviral therapy)], chronic HCV should be treated because there is no need to consider drug drug interactions. In with a CD4 cell count <500 cells/ll, early ART is recommended to slow the progression of fibrosis. Interferon (IFN)-based HCV therapy has been shown to be more successful in HIV with complete suppression of HIV replication. Therefore, in a patient with HIV/HCV co-infection, the CD4 cell count should be improved with ART before beginning anti-hcv treatment if the CD4 cell count <350 cells/ll. Patients with a CD4 relative percentage >25% who receive IFN-based therapy are more likely to achieve SVR than those with a lower CD4 percentage (12). DAA combinations will clearly be used in the future without IFN and RBV and the treatment duration will be shorter making a strong immune system less important than in IFN-based regimens, because these new HCV treatments are not expected to affect the CD4-count. HCV therapy selection depends on the genotype There are several options for HCV therapy. IFN-free and possibly RBV-free regimens should be chosen when available because of shorter treatment, significantly fewer side effects and improved cure rates (13). However, because of costs, access to the newer HCV drugs may be limited in certain countries or regions. In these cases, HCV drug combinations may be needed because cure rates may be significantly improved compared to PEG-IFN/RBV alone. Tables 1 and 2 summarize the IFN-free and IFN-containing HCV regimens for the different HCV genotypes. Sofosbuvir and RBV is the new gold standard therapy for genotype 2 in both treatment na ıve and treatment experienced. This combination provides a cure for HCV in more than 90% of treated. Indeed in the PHOTON 1 and 2 studies, a SVR was achieved at week 12 with sofosbuvir and RBV in 88 and 89% of HCV treatment na ıve and HIV coinfected subjects with HCV genotype 2 infection respectively (14, 15). Longer treatment (16 weeks) may be needed in with cirrhosis. In all other genotypes, despite quite high average response rates above 80%, sofosbuvir and RBV alone are not the preferred option because of higher relapse rates than with two DAA combinations. However, in case of John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
3 Rockstroh Optimal therapy of HIV/HCV co-infected with DAAs Newly diagnosed chronic HCV GT 1 6 infection Perform Fibroscan and/or serum marker and/or liver biopsy F0 F1 * F2 F3 * F4 * In general, treatment can be deferred HCV treatment should be discussed IFN-free HCV treatment needs to be initiated Fig. 1. Management algorithm for HCV of all genotypes. *Metavir fibrosis score: F0 = no fibrosis; F1 = portal fibrosis, no septae; F2 = portal fibrosis, few septae; F3 = bridging fibrosis; F4 = cirrhosis. Table 1. IFN-free HCV treatment options for the various HCV genotypes HCV genotype Treatment Treatment duration in treatment-naive Treatment duration in treatment-experienced 1 & 4 SOF + RBV 24 weeks 24 weeks SOF + SMP 12 weeks (possible extension up to 24 weeks and/or addition of RBV) 12 weeks (possible extension up to 24 weeks and/or addition of RBV) SOF + DCV 12 weeks in non-cirrhotics, 24 weeks in compensated cirrhotics 12 weeks in non-cirrhotics, 24 weeks in compensated cirrhotics 2 SOF + RBV 12 weeks (possible extension weeks up to 16 weeks in cirrhotics) 3 SOF + RBV 24 weeks 24 weeks SOF + DCV + RBV 24 weeks in compensated cirrhotics 24 weeks 5 & 6 In the absence of clinical data on DAAs in HCV GT 5 and 6 infection should be treated similar to HCV GT 1 and 4 infection RBV, ribavirin; SOF, sofosbuvir; SMP, simeprevir; DCV, daclatasvir. Table 2. IFN-containing HCV treatment options for all genotypes HCV genotype Treatment Treatment duration in treatment-naive Treatment duration in treatment-experienced 1 & 4 SOF + PR 12 weeks (possible extension up to 24 weeks in cirrhotics) weeks SMP* + PR 24 weeks (48 weeks in cirrhotics) 48 weeks DCV + PR 24 weeks if RVR, 48 weeks if non-rvr 24 weeks if RVR, 48 weeks if non-rvr 2 PR IFN-free treatment recommended. If SOF not available: PR 24 weeks if RVR, 48 weeks if non-rvr 3 SOF + PR 12 weeks (possible extension up to 24 weeks in cirrhotics) weeks 5 & 6 In the absence of clinical data on DAAs in HCV GT 5 and 6 infection should be treated similar to HCV GT 1 and 4 infection *SMP for 12 weeks only. Also in relapsers. DCV for 24 weeks only. GT 4 only. PR, pegylated interferon + ribavirin; RBV, ribavirin; SOF, sofosbuvir; SMP, simeprevir; DCV, daclatasvir. intolerance to interferon and if other DAAs are not available, a cure is still possible in a high percentage of with the combination of sofosbuvir and RBV. This was especially true in treatment-na ıve genotype three in the PHOTON 2 trial, where 24 weeks treatment was associated with an SVR rate of 89% (15). Sofosbuvir and simeprevir or daclatasvir are clearly the best treatment regimens for with genotypes 1 and 4. Because simeprevir is not active in genotype 3, 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 53
4 Optimal therapy of HIV/HCV co-infected with DAAs Rockstroh the combination of sofosbuvir and daclatasvir is the best treatment regimen. In the near future, other combinations will become available. A fixed dose of sofosbuvir/ledipasvir will probably be available in November 2014 for genotypes 1 and 4. This combination may be used for a shorter duration of 8 weeks in HCV treatment-na ıve without advanced fibrosis. Initial data from an ongoing pilot trial in 50 HCV treatment-na ıve genotype 1 HIV/HCV co-infected reported significant SVR4 rates of 100% (16). The combination paritaprevir/rtv/ombitasvir, 150 mg/ 100 mg/25 mg QD + dasabuvir, 250 mg BID + RBV twice a day (BID = bis in die) is expected to be licensed in early 2015 for genotypes 1 and 4. First results from this combination from the ongoing TURQUOISE trial have shown high SVR4 rates between 93.5 and 96.9 after 12 and 24 weeks of therapy in HIV/HCV coinfected with HCV genotype 1 infection and no prior HCV therapy respectively (17). Drug drug interactions should be carefully checked Drug interactions are common especially in combinations including HCV protease inhibitors, which are metabolized through the cytochrome 450 pathways like HIV Nonnucleoside reverse-transcriptase inhibitors (NNRTIs) or Protease Inhibitors. Therefore, combinations with HIV drugs must be checked on drug interaction websites such as Potential drug drug interactions with sofosbuvir, which is not metabolized by the cytochrome p450 pathway, are low. The only antiretroviral drug which should not be co-administered because of significant interactions is tipranavir. Significant interactions exist with simeprevir, which uses metabolization pathways that are similar to those in HIV protease inhibitors and NNRTIs. Indeed at present other than the NRTI backbones abacavir/3tc or tenofovor/ftc, concomitant use is only recommended with raltegravir, dolutegravir or rilpivirine. For the moment only limited data on PK interactions exist for daclatasvir. Atazanavir/r is the only HIV protease inhibitor that has been evaluated to date. Co-administration is possible but the dose of daclatasvir should be adapted to 30 mg per day. The results of pharmacokinetic interaction studies with other boosted HIV protease inhibitors will be presented at the Conference on Retroviruses and Opportunistic Infections meeting in February Co-administration with efavirenz is possible but because of enzyme induction an increase in the dose of daclatasvir to 90 mg is recommended. Rilpivirine, dolutegravir and raltegravir can be safely co-administered with no change in dose (60 mg per day). Conclusions End-stage liver disease secondary to HIV/HCV coinfection is one of the main causes of mortality in with HIV being treated with ART, because the progression of liver disease associated with HCV infection is accelerated. With the availability of highly active ART, and as live longer, the prevalence of hepatocellular carcinoma is expected to rise. Without early effective HCV treatment, these have a high risk of HCV-related sequelae. Treating HCV in with HIV/HCV co-infection will not only decrease the rate of mortality associated with liver disease and improve the quality of life but it will also improve the outcome of other inflammation-associated comorbidities. IFN and RBV-free therapies are now a reality, promising a cure in most. Indeed, the outcome of treatment in HIV/HCV coinfected and HCV mono-infected subjects is now similar. Unfortunately, the high costs of HCV treatment have limited availability of these new therapies so far. Hopefully as the number of DAA combinations increases and competition grows, prices will fall, allowing broader access to modern HCV therapy. Acknowledgements This study was supported by the DZIF TTU HIV Project , and the German Center for Infection Research (DZIF). Conflict of interest: JKR has recieved honoraria for speaking at educational events or consulting from Abbvie, Bionor, BMS, Gilead, Janssen, Merck, Tibotec, Tobira, and ViiV. References 1. Easterbrook P. Global burden of hepatitis B and C, and HIV co-infection. International HIV/Viral Hepatitis Co- Infection Satellite Meeting Melbourne, July Rockstroh JK, Peters L, Grint D, et al.; EuroSIDA in Euro- Coord. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?. J Hepatol 2013; 59: Morlat P, Roussillon C, Henard S, et al.; ANRS EN20 Mortalite 2010 Study Group. Causes of death among HIV-infected in France in 2010 (national survey): trends since AIDS 2014; 28: Lacombe K, Rockstroh JK. HIV and viral hepatitis coinfections: advances and challenges. Gut 2012; 61(Suppl. 1): i Rockstroh JK, Bhagani S. Managing HIV/hepatitis C coinfection in the era of direct acting antivirals. BMC Med 2013; 11: Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in with HIV: a randomised, double blind, controlled phase 2 trial. Lancet Infect. Dis 2013; 13: Sulkowski M, Sherman K, Dieterich D, et al. Telaprevir in combination with peginterferon and ribavirin for chronic HCV genotype 1 infection in HIV-infected. Ann Intern Med 2013; 159: Cotte L, Braun J, Lascoux-Combe C, et al. Telaprevir for HIV-HCV coinfected failing peginterferon John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
5 Rockstroh Optimal therapy of HIV/HCV co-infected with DAAs ribavirin (ANRS HC26TelapreVIH): an open-label, singlearm, phase 2 trial. Clin Infect Dis 2014; pii: ciu659 [Epub ahead of print]. 9. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011;55: Lo Re V 3rd, Kallan MJ, Tate JP, et al. Hepatic decompensation in antiretroviral-treated co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected : a cohort study. Ann Intern Med 2014; 160: Berenguer J, Zamora FX, Carrero A, et al.; GESIDA HIV- HCV Cohort Study Group. Effects of sustained viral response in with HIV and chronic hepatitis C and nonadvanced liver fibrosis. J Acquir Immune Defic Syndr 2014;66: Opravil M, Sasadeusz J, Cooper DA, et al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in with HIV/ hepatitis C virus coinfection. J Acquir Immune Defic Syndr 2008; 47: Schinazi R, Halfon P, Marcellin P, Asselah T. HCV directacting antiviral agents: the best interferon-free combinations. Liver Int 2014; 34(Suppl. 1): Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in with HIV-1 coinfection. JAMA 2014; 312: Molina JM, Orkin C, Iser DM, et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotypes 1, 2, 3 and 4 infection in co-infected with HIV (PHOTON-2). AIDS th International AIDS Conference. July 20 25, Melbourne. Abstract MOAB0105LB. 16. Osinusi A, Townsend K, Nelson A et al.; NIAID ERADI- CATE Study Team. Use of sofosbuvir/ledipasvir fixed dose combination for treatment of genotype-1 infection in coinfected with HIV. 49thEuropean Association for the Study of the Liver International Liver Congress (EASL 2014). London, April 9 13, Abstract O Sulkowski M, Eron JJ, Wyles D, et al.; TURQUOISE-I: safety and efficacy of ABT-450/r/ombitasvir, dasabuvir, and ribavirin in co-infected with hepatitis C and HIV-1. AIDS th International AIDS Conference. July 20 25, Melbourne. Abstract MOAB0104LB John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 55
SVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
More informationHIV-HCV coinfection. Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland
HIV-HCV coinfection Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland Disclosures Principal investigator for research grants Funds paid to Johns Hopkins
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationDr Janice Main Imperial College Healthcare NHS Trust, London
BHIVA AUTUMN CONFERENCE 2014 Including CHIA Parallel Sessions Dr Janice Main Imperial College Healthcare NHS Trust, London 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationIFN-free therapy in naïve HCV GT1 patients
IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,
More information5/2/2016. Andrew I. Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois. Learning Objectives
Challenges in the Management and Treatment of HIV/Hepatitis C Virus Coinfection Andrew I. Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois FORMATTED: 05/02/2016 Chicago,
More informationCurrent State of Treatment for HCV. Nancy Reau, MD Associate Professor of Medicine University of Chicago
Activity Code FA376 Current State of Treatment for HCV Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives Upon completion of this presentation, learners should be
More informationTreatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain
Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses
More informationHIV/HCV Coinfection: Why It Matters and What To Do About It. Cody A. Chastain, MD 10/26/16
HIV/HCV Coinfection: Why It Matters and What To Do About It Cody A. Chastain, MD 10/26/16 Disclosures I have no relevant financial disclosures. Objectives At the end of this lecture, the learner will be
More informationSeparate clinical trials for HIV- HCV coinfected patients are NOT a necessity. Patrick Ingiliz, Berlin
Separate clinical trials for HIV- HCV coinfected patients are NOT a necessity Patrick Ingiliz, Berlin Back in the days when HCV genotype 1 was the problem SVR (%) 100 90 80 70 60 50 40 30 20 10 0 35% PRESCO
More informationTough Cases in HIV/HCV Coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014
More informationHIV/Hepatitis C in France: data from real life cohorts LIONEL PIROTH CHU DIJON UNIVERSITY OF BURGUNDY DECEMBER LONDON
HIV/Hepatitis C in France: data from real life cohorts LIONEL PIROTH CHU DIJON UNIVERSITY OF BURGUNDY DECEMBER 2015 - LONDON The need Decreasing prevalence of chronic hepatitis C in French people living
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationHepatitis C: a treatment revolution
Sunday, 10th July 2016 Michaelmas Cay 2 Room Concurrent 11 Health Innovation Hepatitis C: a treatment revolution Dr. Heather McNamee Hepatitis C a treatment revolution Dr Heather McNamee Medical Director
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationSection 6: Treatment of Hepatitis C virus (HCV)
Section 6: Treatment of Hepatitis C virus (HCV) Dr. Niklas Luhmann (Médecins du Monde) Training Hepatitis C and HR for PWUD, 9 th -13 th May 2016, Hanoi, Vietnam Learning objective of the session: understanding
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationSHOULD EVERYONE WITH HCV/HIV COINFECTION BE TREATED NOW?
SHOULD EVERYONE WITH HCV/HIV COINFECTION BE TREATED NOW? Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures
More informationUpdates in the Management of HCV: What Clinicians Who Care for Patients With HCV Need to Know Today
Updates in the Management of HCV: What Clinicians Who Care for Patients With HCV Need to Know Today The treatment paradigm for hepatitis C virus (HCV) is changing very rapidly. In the short time since
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationAntiviral treatment in Unique Populations
Antiviral treatment in Unique Populations Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Unique HCV Populations HIV/HCV co-infected
More informationCOMPETING INTEREST OF FINANCIAL VALUE
Sixth Annual BHIVA Conference for the Management of HIV/Hepatitis Co-Infection in collaboration with BASL and BVHG Dr Ed Wilkins North Manchester General Hospital COMPETING INTEREST OF FINANCIAL VALUE
More informationHIV and Hepatitis C Have we finally slayed the beast?
HIV and Hepatitis C Have we finally slayed the beast? Mark W. Sonderup Division of Hepatology Department of Medicine University of Cape Town & Groote Schuur Hospital Accelerated Fibrosis in HIV-HCV co-infected
More informationManagement of HIV/HCV Coinfection. Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY
Management of HIV/HCV Coinfection Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY Disclosure Dr. Marks has received grants and research support from Gilead Sciences
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationSpecial Contribution Highlights of the 2012 American Association for the Study of Liver Diseases Meeting
Special Contribution Highlights of the 20 American Association for the Study of Liver Diseases Meeting Melissa K. Osborn, MD The American Association for the Study of Liver Diseases (AASLD) held its annual
More informationHIV Infection with HCV Future Directions
HIV Infection with HCV Future Directions Dr Ranjababu (Babu) Kulasegaram Consultant Physician in HIV/GU Medicine Guy s and St Thomas NHS Foundation Trust London, UK Presenter disclosure information Dr
More informationCARE FOR PATIENTS WITH CHRONIC HCV/HIV COINFECTIONS
CARE FOR PATIENTS WITH CHRONIC HCV/HIV COINFECTIONS JOHN I. MCNEIL, MD, FACP MAXIMED ASSOCIATES MARYLAND JUNE 8, 2017 CME Disclosures: Planning Committee And Speaker Speaker: The following speaker has
More informationNew Antivirals for Hep C in Context of HIV: Vosevi and Mavyret
New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical
More information10/4/2016. Management of Hepatitis C Virus Genotype 2 or 3 Infection
Management of Hepatitis C Virus Genotype 2 or 3 Infection Kenneth E. Sherman, MD, PHD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati Cincinnati, Ohio FORMATTED:
More informationHIV/HCV coinfection. Jürgen K. Rockstroh, Department of Medicine I, Bonn University Hospital, Bonn, Germany
HIV/HCV coinfection Jürgen K. Rockstroh, Department of Medicine I, Bonn University Hospital, Bonn, Germany Conflict of Interest Honoraria for lectures and/or consultancies from Abbott, AbbVie, Bionor,
More informationTreatment of HCV in Persons with HIV Coinfection
Hepatitis C Online PDF created October 2, 2018, 12:45 pm Treatment of HCV in Persons with HIV Coinfection This is a PDF version of the following document: Section 6: Treatment of Key Populations and Unique
More informationMy HCV patient is co-infected with HIV: how to manage?
EASL «White Nights of Hepatology 2016» My HCV patient is co-infected with HIV: how to manage? A.V. Кravchenko MD, Professor Russia AIDS Federal Center Central Research Institute of Epidemiology St.-Petersburg,
More informationLength of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the medical evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure
More informationWe have been talking about
Positive News Information Magazine for people with Hepatitis C and HIV The Irish Haemophilia Society Representing people in Ireland with haemophilia and related bleeding disorders NEW DAA-Y S DAWN FOR
More informationAri Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College
Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College New York State Law Goes into Effect January 1, 2014 Hepatitis C Virus
More informationCURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationDogma: HCV treatment for eradication. Lisa Barrett MD PhD FRCPC Dept. of Infectious Diseases, Microbiology and Immunology April 18, 2015
Dogma: HCV treatment for eradication Lisa Barrett MD PhD FRCPC Dept. of Infectious Diseases, Microbiology and Immunology April 18, 2015 Disclosures Some discussion of non-hc approved compounds Industry:
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationHIV-HCV Co-Infection. George Mason University Falls Church, Virginia. Overview. Prevalence of HCV co-infection Incidence and Recent Trends
HIV-HCV Co-Infection Zobair Younossi MD, MPH, FACG, AGAF, FAASLD Chairman, Department of Medicine, Inova Fairfax Hospital Vice President for Research, Inova Health System Professor of Medicine, VCU-Inova
More informationGlobal Prevalence of HBV, HCV, HIV
Treatment of Patients with HCV and HIV Paul Y. Kwo, MD, FACG Professor of Medicine Stanford University email: pkwo@stanford.edu Global Prevalence of HBV, HCV, HIV 24 m Journal of Clinical Virology Page
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationHIV/HCV co-infected patients should be prioritised for HCV treatment. Sanjay Bhagani Royal Free Hospital/UCL London
HIV/HCV co-infected patients should be prioritised for HCV treatment Sanjay Bhagani Royal Free Hospital/UCL London Also requires other resources What should a prioritisation process Life-saving at this
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationFollow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France
9th Paris Hepatitis Conference, January 11-12, 2016 Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France Disclosures
More informationHIV/HCV Co-Infection
HIV/HCV Co-Infection 2015 Kentucky Conference on Viral Hepatitis Matt Cave, M.D. Associate Professor Department of Medicine Division of Gastroenterology, Hepatology, & Nutrition Department of Pharmacology
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationHIV coinfection and HCC
HIV coinfection and HCC 3 rd APASL STC on HCC 21 st -23 rd Nov 2013 Cebu, Phillippines George KK Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond) Consultant, Humanity and Health GI
More informationChronic Hepatitis C Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Chronic Hepatitis C Drug Class Prior Authorization Protocol This policy has been developed through review of medical
More informationHIV/hepatitis co-infection. Christoph Boesecke Department of Medicine I University Hospital Bonn Germany
HIV/hepatitis co-infection Christoph Boesecke Department of Medicine I University Hospital Bonn Germany Clinical Management and Treatment of HBV and HCV Co-infection in HIVpositive Persons Hepatitis B
More informationUniversal HCV treatment: Strategies for simplification
Universal HCV treatment: Strategies for simplification PARIS HEPATOLOGY CONFERENCE 3 January 217 Tarik Asselah (MD, PhD) Hepatology & Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationCurrent trends in CHC 1st genotype treatment
Current trends in CHC 1st genotype treatment Tarik Asselah MD, PhD Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France Disclosures Employee of Paris Public University
More informationNEXT GENERATION DIRECT-ACTING ANTIVIRALS
EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN PATIENTS CO-INFECTED WITH HEPATITIS C VIRUS AND HUMAN IMMUNODEFICIENCY VIRUS-1: THE EXPEDITION-2 STUDY J. Rockstroh, K. Lacombe, R. Viani, C. Orkin, D.
More informationEliminating Hepatitis C from New Zealand
Eliminating Hepatitis C from New Zealand Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures I have the following
More informationHCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir
More informationPegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C
Liver International ISSN 1478-3223 REVIEW ARTICLE Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C Nicole M. Welch and Donald M. Jensen University
More informationLength of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure appropriate
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationHCV TREATMENT OPTIONS
HCV TREATMENT OPTIONS Trea2ng HCV is never an emergency, but early treatment prevents further liver damage. DAAs are easier to take, and be0er tolerated than PEG- IFN and RBV. Treatment is recommended
More informationThe HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany
: Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained
More informationM (SAPPHIRE-II)
PRESS RELEASE AbbVie Demonstrates 96 percent SVR 12 in its Phase III Study of Treatment- Experienced Patients with Genotype 1 Hepatitis C Results further confirm phase II studies, with consistent virologic
More informationHCV Treatment: Why to Wait
HCV Treatment: Why to Wait Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est
More informationHIV and Hepatitis C: Advances in Treatment
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and Hepatitis C: Advances in Treatment John Scott, MD, MSc Asst Professor University of Washington Presentation prepared & presented by: John Scott, MD,
More informationDirect acting anti-virals: the near future
Direct acting anti-virals: the near future Heiner Wedemeyer Hannover Medical School Germany Will IFN-free treatment be possible in the near future? Interferon-free regimens to treat hepatitis C What should
More informationInformation Magazine for people with Hepatitis C and HIV. Hepatitis C - Treatment in people with haemophilia, the results to date
Positive News Information Magazine for people with Hepatitis C and HIV Hepatitis C - Treatment in people with haemophilia, the results to date From July 2012 to October 2013, a total of fifteen persons
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis C Drugs(s): Daclatasvir (Daklinza), Dasabuvir/ombitasivir/paritaprevir/ritonavir (Viekira Pak), Elbasvir/grazoprevir (Zepatier), Peginterferon alfa-2a (Pegasys),
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More informationHepatitis C and HIV. Stanislas Pol
Hepatitis C and HIV Stanislas Pol Unité d Hépatologie, Hôpital Cochin Inserm U1223 & USM20 Institut Pasteur Université Paris Descartes Paris, France stanislas.pol@cch.aphp.fr Lisboa, 30 January 2017 Disclosures
More informationUpdate on the Treatment of HCV
Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure
More informationMeet the Professor: HIV/HCV Coinfection
Meet the Professor: HIV/HCV Coinfection Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Division of Infectious Diseases Center for Clinical Epidemiology and Biostatistics University
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationNovember 2013 AASLD Investor Event 4 November
November 2013 AASLD Investor Event 4 November Maris Hartmanis, President and CEO Charlotte Edenius, EVP Development Bertil Samuelsson, CSA Rein Piir, EVP Corporate Affairs & IR Corporate presentation,
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis C Drugs(s): Daclatasvir (Daklinza), Dasabuvir/ombitasivir/paritaprevir/ritonavir (Viekira XR), Elbasvir/grazoprevir (Zepatier), Peginterferon alfa-2a (Pegasys),
More information10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives
A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16
More informationHepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity. Cody A. Chastain, MD
Hepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity Cody A. Chastain, MD Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study
More informationICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationHepatitis C Medications Prior Authorization Criteria
Hepatitis C Medications Authorization Criteria Epclusa (/velpatasvir), Harvoni (ledipasvir/), Sovaldi (), Daklinza (daclatasvir), Zepatier (elbasvir/grazoprevir), Olysio (simeprevir), Viekira Pak (ombitasvir/paritaprevir/ritonavir;
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim (pending P&T approval) Effective Date: July 1, 2018 This policy has been developed through review
More informationTreatment of Hepatitis C with sofosbuvir/ledipasvir (Harvoni )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationHepatitis C Prior Authorization Policy
Hepatitis C Prior Authorization Policy Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review of medical literature,
More informationCan we afford to Cure all HIV-HCV Co-infected Patients of HCV?
Can we afford to Cure all HIV-HCV Co-infected Patients of HCV? Michael S. Saag, MD Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FINAL AU EDITED: 09-17-14 Disclosure Dr
More informationHepatitis C Treatment in Oregon
The Hepatitis C Advisory Group, 12/21/2014 Hepatitis C Treatment in Oregon Introduction The rising health care burden of HCV infection in Oregon is occurring at this time of growing interest in containing
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More informationAbout the National Centre for Pharmacoeconomics
Cost effectiveness of sofosbuvir (in combination with either ribavirin or pegylated interferon + ribavirin) (Sovaldi ) for the treatment of hepatitis C infection The NCPE has issued a recommendation regarding
More informationRecent data in. treatment of acute hepatitis C. Christoph Boesecke Department of Medicine I Bonn University Hospital Bonn, Germany
Recent data in treatment of acute hepatitis C Christoph Boesecke Department of Medicine I Bonn University Hospital Bonn, Germany Conflict of Interest Honoraria for lectures and/or consultancies from abbvie,
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim Criteria Pending P&T Approval Effective Date: August 16, 2018 This drug class prior authorization
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationManagement of HCV Tawesak Tanwandee
Management of HCV 2016 Tawesak Tanwandee Topics Burden of HCV in our countries Natural history and unmet need for HCV treatment Current treatment as for 2016 Conclusion Evolution from HCV infection to
More informationDevelopments in the Treatment of Hepatitis C: A New Era
Developments in the Treatment of Hepatitis C: A New Era Nancy Love, PharmD, BCPS Memorial Medical Center, Johnstown, PA October 17, 2014 Pharmacist Objectives Summarize the results of clinical trials for
More information(differs from NICE who recommend 24 weeks for all) *Child Pugh A only
Treatment Recommendations for the management of patients with Chronic HCV Infection February 2016 These are recommendations for treatment based on a consensus meeting of experienced treating physicians
More informationHepatitis C Introduction and Overview
Hepatitis C Introduction and Overview Michael S. Saag, MD Professor of Medicine Associate Dean of Global Health Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama
More informationHEPATITIS C: UPDATE AND MANAGEMENT
HEPATITIS C: UPDATE AND MANAGEMENT José Franco, MD Professor of Medicine Associate Dean for Educational Improvement Associate Director, Kern Institute STAR Center Director José Franco, MD Disclosures I
More information